I was six years old when open heart surgery saved my brother’s life. It was the first of many times when I thought about becoming a doctor, so that I, too, could save someone’s life. For more than 26 years, I’ve had that opportunity. I’ve treated more than 5,000 patients who’ve had prostate cancer and are now thriving after having their prostate gland removed through a procedure known as radical prostatectomy.
I came to NYU Langone in 1993, because I had a tremendous opportunity to build a world-class urology department here. Since then, our department has defined state-of-the-art care by improving outcomes for radical prostatectomy. For example, we now use a technique that spares the nerves, preserving function as much as possible.
We have also pioneered the use of MRI to diagnose and pinpoint the precise location of prostate cancer. More than 90 percent of patients who’ve needed surgery to remove the prostate at NYU Langone have reported long-term satisfaction with the outcomes.
We are at the forefront of research into prostate cancer, using image-guided diagnostic techniques, such as MRI, to help us determine the best treatment—whether it’s surveillance of slow-growing cancer, the need for complete removal of the prostate, or destroying one malignant area without using surgery.
It's the connection we make with patients and their families that humanizes medicine in this age of technology. For this reason, I take the time to listen to my patients and guide them through treatment, every step of the way.
Conditions and Treatments
- Professor, Department of Urology
- Professor, Department of Biochemistry and Molecular Pharmacology
- Martin Spatz Chair Dept of Urology
- Urology Chief
- American Board of Urology - Urology, 1987
Education and Training
- Residency, Johns Hopkins Hospital, 1985
- Residency, Johns Hopkins Hospital, 1981
- MD from Johns Hopkins University, 1979
Locations and Appointments
- Cigna EPO/POS
- Cigna PPO
Empire Blue Cross Blue Shield
- Empire Blue Cross Blue Shield EPO
- Empire Blue Cross Blue Shield HMO
- Empire Blue Cross Blue Shield Indemnity
- Empire Blue Cross Blue Shield POS
- Empire Blue Cross Blue Shield PPO
- Empire Blue Cross Blue Shield Pathways, Enhanced
- HealthSmart (WTC)
- MagnaCare PPO
- Oxford Freedom
- Oxford Liberty
- UnitedHealthcare Core and Charter
- UnitedHealthcare EPO
- UnitedHealthcare HMO
- UnitedHealthcare POS
- UnitedHealthcare PPO
- UnitedHealthcare Top Tier
“We have worked to improve the technique for removing the prostate, preserving as many nerves as possible.”Herbert Lepor, MD Urologist
Testosterone Deficiency and the Prostate
Alukal, Joseph P; Lepor, Herbert Alukal, Joseph P; Lepor, Herbert
Urologic clinics of North America. 2016 May. 43 (2): 203-208
Risk Stratification by Urinary PCA3 Testing Prior to MRI-US Fusion-Targeted Prostate Biopsy among Men with No Previous History of Biopsy
Fenstermaker, Michael; Mendhiratta, Neil; Bjurlin, Marc A; Meng, Xiaosong; Rosenkrantz, Andrew B; Huang, Richard; Deng, Fang Ming; Zhou, Ming; Huang, William C; Lepor, Herbert; Taneja, Samir S Fenstermaker, Michael; Mendhiratta, Neil; Bjurlin, Marc A; Meng, Xiaosong; Rosenkrantz, Andrew B; Huang, Richard; Deng, Fang Ming; Zhou, Ming; Huang, William C; Lepor, Herbert; Taneja, Samir S
Urology. 2016 Aug 22. ?-?
Re: Complications, Recovery, and Early Functional Outcomes and Oncologic Control following In-Bore Focal Laser Ablation of Prostate Cancer Editorial Comment [Editorial]
Lepor, H; Llukani, E; Sperling, D; Futterer, JJ Lepor, H; Llukani, E; Sperling, D; Futterer, JJ
Journal of urology. 2016 JUN. 195 (6): 1782-1783